Compound amino acid injection for treating nephrosis

A compound amino acid and injection technology, which is applied in medical formula, urinary system diseases, medical preparations containing active ingredients, etc., can solve problems such as increased blood ammonia concentration, disordered plasma amino acid spectrum, and formula limitations, and achieve total nitrogen The effect of increasing the amount of blood, inhibiting the increase of blood amino acid concentration, and promoting the urea cycle

Inactive Publication Date: 2008-12-31
MITSUBISHI PHARMA GUANGZHOU
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] A large number of clinical statistics show that the use of simple essential amino acid preparations during TPN may lead to increased blood ammonia concentration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] Dissolve the following components in distilled water for injection according to the following parts by weight, adjust the pH value of the amino acid solution to neutral, put the solution into a bottle or plastic bag after sterilization and filtration, fill it with nitrogen and seal it, and heat it out according to the conventional method Bacteria, make the present embodiment injection.

[0099] L-Isoleucine 12.3

[0100] L-leucine 16.4

[0101] L-Lysine acetate 11.4

[0102] L-Methionine 8.2

[0103] L-phenylalanine 8.2

[0104] L-Threonine 4.0

[0105] L-Tryptophan 4.0

[0106] L-valine 12.3

[0107] L-alanine 4.9

[0108] L-Arginine 4.9

[0109] L-Aspartic Acid 0.4

[0110] L-glutamic acid 0.4

[0111] L-Histidine 4.0

[0112] L-proline 3.3

[0113] L-serine 1.6

[0114] L-tyrosine 0.8

[0115] Glycine 2.4

[0116] L-cysteine ​​0.4

[0117] Sodium bisulfite 0.4

Embodiment 2

[0119] Prepare the injection of following components and parts by weight according to the method of Example 1:

[0120] L-Isoleucine 10.0

[0121] L-leucine 17.4

[0122] L-Lysine acetate 9.6

[0123] L-Methionine 7.2

[0124] L-phenylalanine 7.2

[0125] L-threonine 4.5

[0126] L-Tryptophan 4.5

[0127] L-valine 11.3

[0128] L-Alanine 4.0

[0129] L-Arginine 4.0

[0130] L-Aspartic Acid 0.6

[0131] L-glutamic acid 0.6

[0132] L-histidine 4.8

[0133] L-Proline 2.5

[0134] L-Serine 1.0

[0135] L-Tyrosine 1.0

[0136] Glycine 1.8

[0137] L-cysteine ​​0.2

[0138] Sodium bisulfite 0.2

Embodiment 3

[0140] Prepare the injection of following components and parts by weight according to the method of Example 1:

[0141] L-Isoleucine 13.5

[0142] L-Leucine 12.0

[0143] L-Lysine acetate 13.8

[0144] L-Methionine 8.9

[0145] L-phenylalanine 8.7

[0146] L-Threonine 3.8

[0147] L-Tryptophan 4.5

[0148] L-valine 11.3

[0149] L-alanine 5.3

[0150] L-Arginine 5.3

[0151] L-Aspartic acid 0.2

[0152] L-glutamic acid 0.2

[0153] L-histidine 2.2

[0154] L-proline 3.8

[0155] L-Serine 2.0

[0156] L-tyrosine 0.3

[0157] Glycine 3.2

[0158] L-cysteine ​​0.6

[0159] Sodium bisulfite 0.6

[0160] The beneficial effects of the injection of the present invention will be further elaborated below through specific clinical trials.

[0161] 1. Controlled clinical trials

[0162] (1) Research methods

[0163] A clinical study was conducted on 125 patients by prospective, random, single-blind, parallel, controlled, multi-center methods. The observation time is 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a compound amino acid injection for curing nephropathy. The present invention is added with tyrosine and typtophane, the demand of which increases in kidney failure, as well as nine unnecessary amino acids, such as arginine which plays an important role in promoting urea circulation and balancing blood amino acid density; the non-protein heat/nitrogen (NPC/N) ratio is decreased from 500 to 1,000 in the past to 300 to 400 or so; the proportion between necessary amino acids and unnecessary amino acids is 3 to 4, thus reducing the weight parts of lysine, methionine, phenylalanine, threonine and histidine which can easily increase the blood concentration when the kidney necessary amino acid preparation is in use. The acid injection of the present invention not only has the effect of the original kidney amino acid preparation of maintaining the kidney function and improving uremia, but also has the obvious effect of improving the nutrition by medication from peripheral vein or central vein.

Description

technical field [0001] The invention relates to a compound amino acid, in particular to a compound amino acid injection for treating nephropathy. Background technique [0002] In the 1980s, my country developed amino acid injections for nephropathy, such as Ministry-issued standard compound amino acid injections (9AA) and Shenan injections. Formula, its ingredients only contain 8 kinds of essential amino acids and histidine, clinically only used to improve the clinical symptoms of patients with chronic renal failure. [0003] In recent years, through a large number of clinical studies, new insights into the condition of renal failure and nutritional support therapy have been obtained: [0004] At the beginning, Giordano proposed "essential amino acid therapy" for renal failure. He believed that: on the premise of supplementing enough calories, by giving essential amino acids, the excessively accumulated urea nitrogen in the body can be reused to synthesize non-essential amin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/04A61P13/12A61K31/198A61K31/401A61K31/405A61K31/4172
Inventor 古川正人
Owner MITSUBISHI PHARMA GUANGZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap